scholarly journals The effect of phenylephrine hydrochloride 2.5 % and sodium hyaluronate solution on visual functions and accommodation in children with myopia and its local tolerability

2022 ◽  
Vol 14 (4) ◽  
pp. 85-94
Author(s):  
E. P. Tarutta ◽  
N. A. Tarasova ◽  
S. V. Milash ◽  
G. A. Markosian ◽  
N. Yu. Kushnarevich ◽  
...  
Keyword(s):  
Sodium Hyaluronate ◽  
Tear Film ◽  
Local Tolerability ◽  
Local Tolerance ◽  
Visual Functions ◽  
Phenylephrine Hydrochloride ◽  
Nearest Point ◽  
Clear Vision ◽  
Break Time ◽  
Surface Examination

Purpose: to evaluate visual functions, accommodation, and local tolerance in children instilled with Phenylephrine hydrochloride 2.5 % and sodium hyaluronate solution (Stelphrin Supra). Material and methods. 30 children (60 eyes) aged 8 to 12 (ave. 10.04 ± 0.24) with low (28 eyes) and moderate (32 eyes) myopia (ave. -2.96 ± 0.17 D) were tested. Refractometry, subjective and objective accommodation, optical biometry, anterior corneal surface examination, Norn test, and polling were performed prior to one-time instillation, 30 minutes after it, and after 1 month of daily bedtime instillations of Stelphrin Supra. Results. We noted a significant decrease in the tone of accommodation in the open field by 90 % from the initial value, an approximation of the nearest point of clear vision by 27 %, an increase in the volume of absolute accommodation by 57 % and the objective amplitude of accommodation by 20 %, which indicates an increase in the accommodation ability. The pupil width increased 30 minutes after a single instillation of Stelphrin Supra, which coincided with an increase in the relative accommodation reserve by 25 % from the initial one. After a month, the pupil width significantly decreased, and the positive relative accommodation reserve decreased to a level only 12 % higher than the original one. Tear film break time significantly increased by 0.89 sec, singular spot stainings disappeared in 2 out of 6 patients, lacrimation — in 6 out of 10, pain — in 1 out of 2, blurring in 4 out of 6, feeling of “sand” — in 7 out of 9 patients who had these symptoms before instillations. Conclusion. Regular instillations of Stelphrin Supra reduce the habitual tone of accommodation, increase the accommodation ability, and improve the condition of the eye surface.

Prospective comparison of subcutaneous to intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and toxicity

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8046-8046 ◽  
Author(s):  
P. Moreau ◽  
V. Coiteux ◽  
C. Hulin ◽  
T. Facon ◽  
H. van de Velde ◽  
...  
Keyword(s):  
Standard Dose ◽  
Area Under The Curve ◽  
Proteasome Inhibition ◽  
Response Rates ◽  
Median Number ◽  
Route Of Administration ◽  
Systemic Availability ◽  
Local Tolerability ◽  
Local Tolerance ◽  
Prospective Comparison

8046 Bortezomib (Bz) is a novel proteasome inhibitor that is registered for treatment of relapsed or refractory MM as an IV bolus injection. Animal toxicology studies have indicated good local tolerability and an acceptable PK profile of SC injection of Bz supporting together with preliminary clinical data the exploration of this route of administration in humans. We conducted a randomized trial to compare pharmacokinetics/pharmacodynamics (PK/PD), toxicity and efficacy of SC and IV injections of Bz, both at standard dose of 1.3 mg/m2 twice weekly for 2 wks (day 1–4-8–11), with 1 wk rest, for up to 8 cycles. From 01/06 to 10/06, 24 pts with relapsed/refractory MM were randomized to receive Bz either IV (arm A, n = 12) or SC (arm B, n = 12); Patients received a median number of 5 cycles in both groups. The local tolerance of SC injections was good. Response rates were similar in both groups (CR+VGPR/PR/MR: 3/2/1 in arm A, vs 3/2/2 patients in arm B. Grade 3 / 4 adverse events occurred in 7 cases in arm A, vs 5 in arm B, leading to study discontinuation in 5 and 3 cases, respectively. PK analysis: average plasma Cmax values were lower for SC as compared to IV (15 ng/mL at day 1, and 23 at day 11, vs 130 and 127, p < .001), but overall systemic availability as measured by plasma AUC values were comparable between SC and IV administration for both day 1 & 11 (145 and 388 ng.h/mL, vs 133 and 386, p =.7 & .98, respectively). Average Tmax values were less than 1 hour for both routes. PD analysis (20S proteasome inhibition): average area under the curve for effect (AUE) values were comparable between SC and IV administration both for day 1 & 11 (761 and 1,324 %.h, vs 1,089 and 1,110, p = .29 & .54, respectively), while average Emax values were lower for SC administration (Emax day 1 & day 11 SC, 58 and 56%, vs 72 and 69% IV, p =.003 & .01 respectively). The overall systemic availability of Bz was comparable between SC and IV administration for both day 1 and 11. Similarly, the average AUE results were comparable between SC and IV, while average Emax was lower for SC administration. Response rates were identical in the 2 groups of patients, with similar toxicity profile. Given the good local tolerance of SC injection, this route of administration could be an alternative option to IV injection. [Table: see text]

scholarly journals Efficacy of carbomer sodium hyaluronate trehalose vs hyaluronic acid to improve tear film instability and ocular surface discomfort after cataract surgery

2019 ◽  
Vol Volume 13 ◽  
pp. 1157-1163 ◽  
Author(s):  
L Caretti ◽  
A La Gloria Valerio ◽  
R Piermarocchi ◽  
G Badin ◽  
G Verzola ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Cataract Surgery ◽  
Ocular Surface ◽  
Sodium Hyaluronate ◽  
Tear Film ◽  
Film Instability

scholarly journals Evaluation of protection against desiccation with different artificial tears containing 0.1%-0.3% hyaluronic acid in experimental dry eye model

2020 ◽  
Author(s):  
Fatma Ahmed ◽  
Frank Tost ◽  
Rico Großjohann ◽  
Carmen Wolke ◽  
Uwe Lendeckel
Keyword(s):  
Hyaluronic Acid ◽  
Cell Line ◽  
Dry Eye ◽  
Exposure Time ◽  
Ionic Composition ◽  
Sodium Hyaluronate ◽  
Tear Film ◽  
Epithelial Cell Line ◽  
Film Instability

Abstract Background: Tear film instability, hyperosmolarity, ocular surface inflammation, apoptosis and neuro-sensory abnormalities are causes of dry eye. Lubricant target tear film instability, the most effective agent for tear film stabilization being Sodium Hyaluronate 0.1 -0.3%. Sodium Hyaluronate is suggested to be protective for epithelium in dry eye. To test this hypothesis, this study was performed in vitro with commercially available solutions containing hyaluronic acid (HA) in concentrations ranging from 0.1 to 0.3%. To evaluate the desiccation protection capability of different Sodium Hyaluronate 0.1 to 0.3%, we employed a reproducible in vitro cell culture system. Methods: Conjunctival (Chang 1-5c-4) and corneal cells (pRSV-T 2.040) were cultivated under standard conditions. Under confluent cell growth cells, conjunctival epithelial cell line Chang 1-5c-4 and the corneal cell line 2.040 pRSV-T were wetted for 20 min with five commercial ophthalmic solutions and one agent in trial phase (sample 1: 0.1% HA; sample 2: 0.3% HA; sample 3: 0.15% HA, 2% dexpanthenol, sodium chloride; sample 4: 0.1% HA; sample 5: 0.2% HA; sample 6: unknown, PBS as negative control, unsupplemented medium as positive control). After 20 minutes cells were exposed to continuous air flow for 0, 15, 30 and 45 minutes. Assessment of viable cells was performed by alamarBlue® assay and LIVE/DEAD® Viability/ Cytotoxicity Kit. Results: It has been shown that both cell lines showed different response to protection by the tested solutions. Greatest protection was observed at 15 minutes with most agents. Best results in protection from desiccation was assessed with sample 2 even at maximum exposure time at 45 minutes. Sample 2 showed an average survival rate of 91% at 45 minutes exposure time, whereas no significant amount of vital cells were detected after application with sample 6. Sample 6 was the only substance that presented with early significant cell loss at 0 and 15 minutes by 35%. Conclusions: Higher concentration of Hyaluronate acid with 0.3% and an ionic composition close to the normal tearfluid seem to provide the best protective effect against desiccation in experimental dry eye.

scholarly journals The Choice of Dry Eye Therapy Depending on Ocular Surface Condition

2021 ◽  
Vol 18 (2) ◽  
pp. 346-354
Author(s):  
S. V. Yanchenko ◽  
A. V. Malyshev ◽  
S. N. Sakhnov
Keyword(s):  
Dry Eye ◽  
Surface Condition ◽  
Sodium Hyaluronate ◽  
Tear Film ◽  
Statistical Processing ◽  
Water Type ◽  
Therapy Effectiveness ◽  
Group 2 ◽  
Deficiency Group ◽  
Group 1

Purpose: to develop approaches to differentiated substitution therapy in patients with dry eye (DE) of mild and moderate severity.Patients and methods. We examined 86 DE patients (22–45 years old; 38 men, 48 women). Group-1 included 54 patients (54 eyes) with mild DE under conditions of combined lipid-mucose-deficiency, group-2 32 patients (32 eyes) with moderate DE against the background of combined lipid-aqua-mucose-deficiency. Conducted: DE symptoms registration (OSDI scale); Norn and Shirmer-1 tests; OCT meniscometry; assessment of the Bijsterveld xerosis index and ‘lid-vipers’ symptom identification; Norn’s compression test. To assessment the therapy effectiveness, patients in both groups were divided into subgroups. Patients of subgroup 1.1 (18 eyes) carried out ‘fat-water’ type emulsion instillations, subgroup 1.2 (18 eyes) — 0.15 % sodium hyaluronate instillation (Hylabak®), subgroup 1.3 (18 eyes) — 3.0 % trehalose (Thealoz®) — 1–2 drops, 4 times a day. All persons included in group-1 were additionally recommended to apply 5.0 % dexpanthenol gel at night. Patients of subgroup 2.1 (16 eyes) received 0.15 % sodium hyaluronate instillation (Hylabak®), patients of subgroup 2.2 (16 eyes) 0.15 % sodium hyaluronate (Hylabak®) and 3.0 % trehalose (Thealoz®) instillation — 4 times a day. All patients included in group-2 were additionally recommended to apply ointment with vitamin A at night. The main criterion for the therapy effectiveness was the tear film brake up time (TBUT, s) two months after the start treatment. Statistical processing included: calculation the mean and its standard deviation (M ± s); assessment of the significance of differences (Wilcoxon’s t-test, KruskalWallis test, Mann-Whitney U-test).Results. In group-1 patients the following TBUT dynamics was recorded: in subgroup 1.1 — from 5.4 ± 0.5 to 6.2 ± 0.6 s (p < 0.05); in subgroup 1.2 — from 5.2 ± 0.4 to 6.6 ± 0.6 s (p < 0.05); in subgroup 1.3 — from 5.3 ± 0.5 to 7.1 ± 0.7 s (p < 0.05). The most pronounced TBUT increase was noted in subgroup 1.3 (trehalose instillation). In group-2, the increase in TBUT was: in subgroup 2.1 — from 3.5 ± 0.3 to 4.7 ± 0.3 s (p < 0.05); in subgroup 2.2 — from 3.4 ± 0.2 to 5.2 ± 0.4 s (p < 0.05). A significantly more pronounced TBUT increase was noted in subgroup 2.2 (sodium hyaluronate and trehalose instillation).Conclusion. In our opinion, differentiated approaches to DE replacement therapy may be included: for mild DE in conditions of lipid-mucose-deficiency — instillation of bioprotector based on 3.0 % trehalose (Thealose®); in case of moderate DE against the background of lipid-aqua-mucose-deficiency — 0.15 % sodium hyaluronate (Hylabak®) instillation in combination with a bioprotector based on 3.0 % trehalose (Thealoz®). 

scholarly journals New Possibilities of Tear Replacement Therapy in Patients with Dry Eye Syndrome of Various Origins

2019 ◽  
Vol 16 (2) ◽  
pp. 244-251
Author(s):  
V. V. Brzheskiy ◽  
S. Yu. Golubev ◽  
I. V. Brzheskaya ◽  
V. Yu. Popov
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Sodium Hyaluronate ◽  
Tear Film ◽  
Severe Form ◽  
Dry Eye Syndrome ◽  
Degenerative Changes ◽  
Ocular Surface Disease Index ◽  
Film Stability ◽  
Days Of Therapy

The artificial tears on the basis hyaluronic acid is primary importance today in dry eye syndrome (DES) treatment. In recent years, they have been supplemented Optinol® Express Moisture (0.21 %) and Optinol® Deep Moisture (0.4 %) differing concentrations of sodium hyaluronate and viscosity. The study is devoted to assessing the effectiveness of these drugs in the treatment of patients with dry eye syndrome (DES) of various etiology and severities.There were 73 volunteers with DES of various etiology: 21 — Sjogren’s syndrome, 24 — meibomian blepharitis, and 28 — perimenopause in the study. All patients were divided into 2 groups: 36 patients of the first group received instillations into conjunctival cavity of the Optinol® Express Moisture (0.21 %) and 37 patients of the second group — Optinol® Deep moistening (0.4 %).Starting from the first days of therapy, all patients had a decrease in the severity of subjective signs of DES, estimated by the value of the ocular surface disease index (OSDI). At the same time, tendency to stop of the degenerative changes in the epithelium of the ocular surface was established. It is characterized by a decrease in the degree of staining. The increasement of the tear film stability and an index of the tear meniscus was found in all patients. The dynamics of the controlled parameters increased, as the instillation of the drugs took place and by the 30th day of therapy. There were significant differences from the baseline values. At the same time, the Optinol® Express Moisture (0.21 %) was more effective (mainly in terms of subjective discomfort and the severity of degenerative changes in the epithelium of the ocular surface) in patients with mild and extremely severe form of the xerosis process.The drug Optinol® Deep Moisture (0.4 %) was more effective in patients with xerosis of moderate severity and severe by the same parameters. In the course of research, we have not observed any side effects of both drugs. It allows us to recommend the drugs Optinol® Express Moisture (0.21 %) and Optinol® Deep Moisture (0.4 %) to widespread clinical use in treating patients with DES of various etiology. 

scholarly journals Clinical study of the efficacy of low molecular weight sodium hyaluronate in complex treatment of corneal graft disease

2020 ◽  
Vol 17 (2) ◽  
pp. 170-177
Author(s):  
G. R. Semak
Keyword(s):  
Molecular Weight ◽  
Sodium Hyaluronate ◽  
Tear Film ◽  
Corneal Graft ◽  
Low Molecular Weight ◽  
Ocular Surface Disease Index ◽  
Disease Treatment ◽  
Graft Disease ◽  
Objective Indicators

The results of corneal graft disease treatment using low molecular weight sodium hyaluronate are presented.The study included 19 patients (20 eyes) aged 24 to 87 years, who developed graft disease after keratoplasty because of chronic dystrophic corneal diseases. The severity of symptoms during treatment was evaluated weekly during the course of therapy using the OSDI (Ocular Surface Disease Index). To assess the dynamics of objective signs of Dry eye disease in dynamics, visometry, biomicroscopy, Schirmer’s test and LIPCOF test were performed weekly before the next injection. A follow-up study was carried out a week after the last injection, with a 1-year dynamic observation following the treatment.Changes in objective indicators of the anterior eye surface were characterized by positive dynamics during therapy. The Schirmer test (p < 0.00001) increased most rapidly and significantly with a lasting effect for a month, demonstrating a beneficial therapeutic effect on both the aqueous and mucinous layer of the tear film. A decrease in the OSDI index was noted after the first injection and decreased progressively during the course of treatment and after its completion up to one month after the last injection (p < 0.00001).

Local Tolerance and Biodegradability of a Novel Artificial Dura Mater Graft Following Implantation Onto a Dural Defect in Rabbits

2020 ◽  
Vol 48 (6) ◽  
pp. 738-746
Author(s):  
Yuval Ramot ◽  
Sagi Harnof ◽  
Ido Klein ◽  
Netanel Amouyal ◽  
Michal Steiner ◽  
...  
Keyword(s):  
Dura Mater ◽  
Healing Process ◽  
Collagen Matrix ◽  
Dural Defect ◽  
Local Tolerability ◽  
Local Tolerance ◽  
Bovine Collagen ◽  
Tissue Healing ◽  
Dural Graft ◽  
Synthetic Grafts

Dura mater defects are a common problem following neurosurgery. Dural grafts are used to repair these defects; among them are biodegradable polymeric synthetic grafts. ArtiFascia is a novel synthetic and fibrous Dural graft, composed of poly(l-lactic-co-caprolactone acid) (PLCL) and poly(d-lactic-co-caprolactone acid). In this study, the biodegradability and local tolerance of ArtiFascia was evaluated in rabbits and compared with a bovine collagen matrix as a reference control. ArtiFascia implantation resulted in the formation of neo-dura at the site of implantation and recovery of the dural damage and the calvaria bone above. The implanted graft was completely absorbed after 12 months and the remaining macrophages were morphologically consistent with the anti-inflammatory M2-like phenotype, which contributes to tissue healing and are not pro-inflammatory. The site of the drilled skull bone had a continuous smooth surface, without exuberant tissue or inflammation and a newly formed trabecular bone formation indicated the healing process of the bone. These results support the local tolerability and biodegradability of ArtiFascia when used as a dural graft in rabbits. This study suggests that PLCL-based grafts including ArtiFascia are safe and effective to repair Rabbit Dura.

Sign in / Sign up

Export Citation Format

Share Document